SCHEDULE OF WARRANT ACTIVITY (Details) - $ / shares |
3 Months Ended | |
|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||
| Weighted Average Exercise Price, Outstanding beginning | $ 6.81 | $ 7.31 |
| Weighted Average Exercise Price, Exercised | 0.97 | |
| Weighted Average Exercise Price, Forfeited | 6.08 | 9.75 |
| Weighted Average Exercise Price, Outstanding beginning | $ 6.80 | $ 6.86 |
| Warrant [Member] | ||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||
| Number of Warrants, Beginning balance | 1,588,417 | 1,523,667 |
| Weighted Average Exercise Price, Outstanding beginning | $ 5.50 | $ 4.30 |
| Number of Warrants, Issued | ||
| Weighted Average Exercise Price, Issued | ||
| Number of Warrants, Exercised | (1,266,667) | |
| Weighted Average Exercise Price, Exercised | $ 4.19 | |
| Number of Warrants, Forfeited | ||
| Weighted Average Exercise Price, Forfeited | ||
| Number of Warrants, Ending balance | 321,750 | 1,523,667 |
| Weighted Average Exercise Price, Outstanding beginning | $ 8.87 | $ 4.30 |
| X | ||||||||||
- Definition Nonoption weighted average exercise price issued. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of non-option equity instruments exercised by participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Net number of non-option equity instruments granted to participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of equity instruments other than options outstanding, including both vested and non-vested instruments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Weighted average price at which option holders acquired shares when converting their stock options into shares. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|